$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
ALX Oncology raises $105M in Series C round for checkpoint inhibitor development
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
Single-letter gene editing startup Beam Therapeutics raises $135M Series B round
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Erasca launches with $42M in Series A funding with ‘erasing cancer’ as its goal
The company expects the funding to bring it into the clinic and is also in partnering talks with academic institutions and biopharma companies, said co-founder Jonathan Lim, who previously led Ignyta.
Orchard Therapeutics closes $150 million Series C round
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
C4 Therapeutics launches with $73M Series A for new cancer treatment approach
The startup created from Dana-Farber Cancer Institute announced today the closing of a $73 million Series A round of financing and a promising partnership with Roche.